Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Med-X launched a Reg A+ raise of up to US$10m at US$4.00 per share.
  • The company withdrew an IPO attempt in April 2024 but maintains Nasdaq ambitions.
  • Nasdaq rule changes in 2025 may introduce tighter listing requirements for small caps.

Med-X, Inc. describes itself as a “green-tech” consumer products company. Its operations span three divisions: Nature-Cide (natural pest control), Thermal-Aid (natural pain relief), and Malibu Brands (wellness). The company positions its product mix as “all-natural bio-solutions” distributed through retail and professional channels.

Recent company statements, press releases, and investor-relations updates consistently highlight aspirations to list on the Nasdaq Capital Market under the reserved ticker “MXRX.” These aspirations are tied to growth initiatives, capital raising, and the company’s belief in aligning its stock with a national exchange.

Capital Raising and Nasdaq Preparation

On May 30, 2025, Med-X launched a Regulation A+ equity offering, seeking to raise up to US$10 million at US$4.00 per share, with a minimum investment size of US$600. The offering was positioned as funding for commercialization and growth activities. Importantly, Reg A+ raises can also expand public float and shareholder count, both key components of meeting Nasdaq’s listing thresholds.

The move comes after a history of capital markets efforts. Between 2022 and 2024, Med-X filed multiple S-1 registration statements, including one with an offering structure around US$4.15 per unit. In April 2024, however, the company withdrew its IPO, a fact reported by The Wall Street Journal. That decision reflected market or internal readiness challenges, underscoring that intent alone does not guarantee an exchange listing.

Nasdaq Standards in Context

For companies of Med-X’s scale, the Nasdaq Capital Market (NCM) is the most likely venue. The NCM has multiple alternative entry standards, which include:

  • A minimum bid price of US$4.00 at listing;
  • Shareholder base thresholds (approximately 300 round-lot holders and 500,000 public shares);
  • Minimums for public float market value;
  • Corporate governance requirements, such as independent directors and audit committees.

Nasdaq has recently proposed tighter initial listing standards (as of September 2025), particularly focused on liquidity and float. If approved, these changes could narrow the window for small-cap issuers like Med-X to qualify under current benchmarks.

Key Unknowns and Risks

Despite visible signals of preparation, several uncertainties remain:

  • Regulatory filings: No new S-1 or updated registration statement has been publicly filed since the 2024 withdrawal.
  • Listing criteria: Public float, equity levels, and round-lot holder counts are not yet disclosed.
  • Market conditions: Shifts in small-cap risk appetite could affect timing.
  • Execution in core businesses: Sustainable revenue and margin performance across Nature-Cide, Thermal-Aid, and Malibu Brands remain essential.

Outlook

Med-X’s communications, financing activities, and Nasdaq messaging suggest the company is preparing for a renewed attempt at uplisting. The Reg A+ round, reserved ticker, and ongoing IR activity all align with that objective. However, there is no confirmed approval or definitive timetable as of September 22, 2025. The outcome depends on Med-X meeting the Nasdaq’s quantitative and governance thresholds while navigating evolving listing rules and market dynamics.